title: Clinical outcomes with drug-eluting and bare-metal stents in patients with ST-segment elevation myocardial infarction: evidence from a comprehensive network meta-analysis.
abstract: OBJECTIVE
  The authors investigated the relative safety and efficacy of different drug-eluting stents (DES) and bare metal stents (BMS) in patients with ST-segment elevation myocardial infarction (STEMI) using a network meta-analysis.
  
  
  BACKGROUND
  The relative safety of DES and BMS in patients with STEMI continues to be debated, and whether advances have been made in this regard with second-generation DES is unknown.
  
  
  METHODS
  Randomized controlled trials comparing currently U.S. approved DES or DES with BMS in patients with STEMI were searched using MEDLINE, EMBASE, and Cochrane databases. Information on study design, inclusion and exclusion criteria, sample characteristics, and clinical outcomes was extracted.
  
  
  RESULTS
  Twenty-two trials including 12,453 randomized patients were analyzed. At 1-year follow-up, cobalt-chromium everolimus eluting stents (CoCr-EES) were associated with significantly lower rates of cardiac death or myocardial infarction (MI) and stent thrombosis (ST) than BMS. Differences in ST were apparent as early as 30 days and were maintained for 2 years. CoCr-EES were also associated with significantly lower rates of 1-year ST than paclitaxel-eluting stents (PES). Sirolimus-eluting stents (SES) were also associated with significantly lower rates of 1-year cardiac death/myocardial infarction than BMS. CoCr-EES, PES, and SES, but not zotarolimus-eluting stents, had significantly lower rates of 1-year target vessel revascularization (TVR) than BMS, with SES also showing lower rates of TVR than PES.
  
  
  CONCLUSIONS
  In patients with STEMI, steady improvements in outcomes have been realized with the evolution from BMS to first-generation and now second-generation DES, with the most favorable safety and efficacy profile thus far demonstrated with CoCr-EES.
authors.affiliation: Dipartimento Cardiovascolare, Policlinico Sant' Orsola, Bologna, Italy.
authors.forename: Tullio
authors.initials: T
authors.lastname: Palmerini
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Biondi-Zoccai
authors.forename: Diego
authors.initials: D
authors.lastname: Della Riva
authors.forename: Andrea
authors.initials: A
authors.lastname: Mariani
authors.forename: Manel
authors.initials: M
authors.lastname: Sabaté
authors.forename: Marco
authors.initials: M
authors.lastname: Valgimigli
authors.forename: Giacomo
authors.initials: G
authors.lastname: Frati
authors.forename: Elvin
authors.initials: E
authors.lastname: Kedhi
authors.forename: Pieter C
authors.initials: PC
authors.lastname: Smits
authors.forename: Christoph
authors.initials: C
authors.lastname: Kaiser
authors.forename: Philippe
authors.initials: P
authors.lastname: Genereux
authors.forename: Soren
authors.initials: S
authors.lastname: Galatius
authors.forename: Ajay J
authors.initials: AJ
authors.lastname: Kirtane
authors.forename: Gregg W
authors.initials: GW
authors.lastname: Stone
mesh_terms: D054855:Drug-Eluting Stents; D000068338:Everolimus; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage; D009203:Myocardial Infarction / Q000628:therapy*; D017239:Paclitaxel / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic; D020123:Sirolimus / Q000008:administration & dosage / Q000031:analogs & derivatives; D015607:Stents; D016896:Treatment Outcome; D050257:Tubulin Modulators / Q000627:therapeutic use
chemical_list: D007166:Immunosuppressive Agents; D050257:Tubulin Modulators; D000068338:Everolimus; D017239:Paclitaxel; D020123:Sirolimus
keywords: BMS; CoCr-EES; DES; PC-ZES; PCI; PES; PRISMA; Preferred Reporting Items for Systematic Reviews and Meta-analyses; RCT; SES; ST-segment elevation acute myocardial infarction; STEMI; StThr; TVR; bare-metal stent(s); cobalt-chromium everolimus-eluting stent(s); drug-eluting stent(s); meta-analysis; paclitaxel-eluting stent(s); percutaneous coronary intervention; phosphorylcholine-based zotarolimus-eluting stent(s); randomized controlled trial; sirolimus-eluting stent(s); stent thrombosis; target vessel revascularizations